{
    "nct_id": "NCT03962543",
    "official_title": "A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity",
    "inclusion_criteria": "* Participant has documented NF1 mutation or a diagnosis of neurofibromatosis type 1 (NF1) using National Institute of Health (NIH) Consensus Conference criteria inclusive of the presence of a plexiform neurofibroma (PN).\n* Participant has a PN that is causing significant morbidity.\n* Participant has a PN that cannot be completely surgically removed.\n* Participant has a target tumor that is amenable to volumetric MRI analysis.\n* Participant is willing to undergo a tumor biopsy pre and post treatment if â‰¥ 18 years of age.\n* Participant has adequate organ and bone marrow function.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 2 Years",
    "exclusion_criteria": "* Participant has abnormal liver function or history of liver disease.\n* Participant has lymphoma, leukemia or any malignancy within the past 5 years (except for resected basal/squamous skin carcinomas without metastases within 3 years).\n* Participant has breast cancer within 10 years.\n* Participant has active optic glioma or other low-grade glioma requiring treatment.\n* Participant has abnormal QT interval corrected or other heart disease within 6 months.\n* Participant has a history of retinal pathology, risk factors for retinal vein occlusion or has a history of glaucoma.\n* Participant has known malabsorption syndrome or gastrointestinal conditions that would impair absorption of mirdametinib (PD-0325901).\n* Participant has received NF1 PN-targeted therapy within 45 days.\n* Participant previously received or is currently receiving therapy with mirdametinib (PD-0325901) or any other MEK1/2 inhibitor.\n* Participant has received radiation therapy within 6 months or has received radiation to the orbit at any time.\n* Participant is unable to undergo or tolerate MRI.\n* Participant has active bacterial, fungal or viral infection.\n* Participant has experienced other severe acute or chronic medical or psychiatric conditions within 1 year.",
    "miscellaneous_criteria": "Key"
}